Sanara MedTech Reports Third Quarter 2026 Financial Results and Updates Full-Year Guidance

Sanara MedTech Inc. reported third quarter 2026 net revenue of $28.4 million, an 8% increase compared to $26.3 million in the same period of 2025. The company recorded a gross profit of $26.3 million, maintaining a 93% gross margin. Operating income was $0.7 million, impacted by approximately $3.0 million in legal and advisory costs related to the company's pending merger with MiMedx Group, Inc. Net loss from continuing operations was $1.3 million, or $0.15 per diluted share, compared to net income of $0.8 million in the prior-year quarter. Additionally, the company updated its full-year 2026 net revenue guidance to a range of $110 million to $115 million, down from its previous forecast of $116 million to $121 million.